Which agent is an IL-23 inhibitor used in psoriatic arthritis?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $24.99Unlock all

Prepare for the CMS II Rheumatology E1 Exam with our comprehensive quiz. Study using flashcards and multiple-choice questions, each with hints and explanations. Get ready for success!

Multiple Choice

Which agent is an IL-23 inhibitor used in psoriatic arthritis?

Explanation:
Blocking IL-23 with a p19-targeted antibody reduces the Th17-driven inflammation that underlies psoriatic arthritis. Guselkumab binds the p19 subunit of IL-23, preventing its signaling and lowering IL-17–mediated inflammation, which helps improve psoriatic arthritis symptoms. The other options target different parts of the inflammatory pathway: IL-17A inhibitors (secukinumab and ixekizumab) block the downstream effects of IL-17A itself, while ustekinumab blocks IL-12 and IL-23 by targeting the p40 subunit, making it not a pure IL-23 inhibitor. Thus, guselkumab is the IL-23 inhibitor used in psoriatic arthritis.

Blocking IL-23 with a p19-targeted antibody reduces the Th17-driven inflammation that underlies psoriatic arthritis. Guselkumab binds the p19 subunit of IL-23, preventing its signaling and lowering IL-17–mediated inflammation, which helps improve psoriatic arthritis symptoms. The other options target different parts of the inflammatory pathway: IL-17A inhibitors (secukinumab and ixekizumab) block the downstream effects of IL-17A itself, while ustekinumab blocks IL-12 and IL-23 by targeting the p40 subunit, making it not a pure IL-23 inhibitor. Thus, guselkumab is the IL-23 inhibitor used in psoriatic arthritis.

More Multiple Choice Questions
Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy